Chrysalis International, MDS deal

MDS invested $5 million in CRLS through a subordinated debenture that bears 6 percent interest. MDS can convert the debenture into 2 million CRLS common shares at $2.50 a share, giving MDS a 15 percent interest in the company. The investment was made as part of an agreement to explore the linking of drug development services between CRLS and MDS’s MDS Pharmaceutical Services Division (Princeton, N.J.), a CRO. ...